The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Methods of improving visual endpoints related to retina-associated disease with CCR3 modulating agents are provided. An example of such an endpoint is visual acuity. Retina-associated diseases upon which visual acuity and other visual endpoints may be improved include retinopathy of prematurity, age-related macular degeneration, central retinal vein occlusion, and diabetic retinopathy.

A pharmaceutical formulation is provided comprising combination of anti-tuberculosis drug drugs optionally in combination of bioenhancers. The formulation is used for the treatment of diseases caused by mycobacterium tuberculosis. The process of preparation of the formulation is also provided.

A composition for coating an edible substrate including about 85.0 wt % to about 95.0 wt % of a cellulose film former (e.g., hydroxypropyl methyl cellulose), about 5.0 wt % to about 15.0 wt % of a plasticizer (e.g., glycerin), and about 1.0 wt % to about 4.0 wt % of a lubricant selected from sunflower oil, vegetable oil, hydrogenated vegetable oil, mineral oil, a fatty acid, or a combination thereof, relative to the total weight of non-water components of the composition. The composition may be applied to a nutritional supplement, a pharmaceutical, a tablet, a capsule, a softgel, a granule, a microparticle, a nanoparticle, a seed, a sugar sphere, gum chew base, chewable gel, or a gummy substrate.

The present disclosure provides dosage form coating compositions and suspensions, coatings, coated dosage forms, and methods of making and using the same. The dosage form coating compositions can include a hydroxypropyl cellulose and a carboxymethylcellulose. The hydroxypropyl cellulose can be present in an amount by weight of at least 18.0% and at most 25.0%. The hydroxypropyl cellulose can be present in a ration of at least 1:1.4 and at most 1.4:1 relative to the carboxymethyl cellulose. The coated dosage forms can have an improved slip force, an improve swallowability as represented by an incline transit distance, or an improved gloss.

The invention relates to a composition that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent. It also relates to a liquid suspension that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and/or (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent; and wherein the multi-particulates are suspended in a liquid comprising a viscosity modifier and a flavoring agent. The invention also relates to kits containing these multi-particulates, and methods of making and using them.

Provided is a novel coating composition for oral solid preparations. The coating composition for oral solid preparations comprises a polyvinyl alcohol-based polymer (a), a fatty acid ester of a polyol having 3 or more hydroxy groups (b), and talc (c),

wherein the fatty acid ester of a polyol having 3 or more hydroxy groups (b) has a hydrophilic lipophilic balance (HLB) value of 4.0 or more;
wherein the fatty acid ester of a polyol having 3 or more hydroxy groups (b) has 12 to 22 carbon atoms per fatty acid ester unit; and
wherein the talc (c) is present at 50% by mass or less of the whole composition.

The present invention relates to oral pharmaceutical compositions comprising eluxadoline or a prodrug or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, and process for the preparation thereof and administration of such compositions for irritable bowel syndrome (IBS-D).

Pharmaceutical coatings obtained from coating compositions based on film-forming copolymers of N,N-diethylaminoethyl methacrylate (DEAEMA) and methyl methacrylate (MMA) comprising a weight ratio of DEAEMA:MMA in the range of 35:65 to 55:45, where the copolymers are present partially neutralized with C.sub.3-C.sub.10-dicarboxylic acids.

The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioactive agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.